Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$4.85 – $12.60
63% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $213.0M | $256.6M | $176.3M | $235.3M | $140.7M | $46.8M | $29.6M | $6.4M |
| Cost of revenue | $235.8M | $1.1M | $8.9M | $449.2M | $20.3M | $4.0M | $15.6M | $0 |
| Gross profit | −$22.9M | $255.4M | $167.4M | −$213.9M | $120.5M | $42.8M | $14.1M | $0 |
| Gross margin | -10.7% | 99.6% | 95.0% | -90.9% | 85.6% | 91.5% | 47.5% | 0.0% |
| R&D | $235.8M | $209.3M | $252.9M | $387.0M | $296.8M | $266.5M | $95.7M | $23.5M |
| Operating income | −$86.7M | −$89.3M | −$191.9M | −$288.5M | −$301.0M | −$322.7M | −$150.4M | −$45.9M |
| EBITDA | −$68.6M | −$52.3M | −$164.3M | −$333.7M | −$282.8M | −$305.2M | −$142.4M | −$45.9M |
| Net income | −$86.4M | −$77.0M | −$189.3M | −$290.0M | −$293.7M | −$284.2M | −$47.6M | $183.5M |
| Net margin | -40.6% | -30.0% | -107.4% | -123.3% | -208.7% | -607.3% | -160.6% | 2848.6% |
| EPS (diluted) | -1.03 | -0.89 | -2.11 | -3.15 | -3.15 | -2.92 | -0.48 | 45.37 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6M | $-11.95 | $-17.39–$-6.51 | 2 |
| 2027 | $6M | $-14.65 | $-20.14–$-9.16 | 2 |
| 2028 | $6M | $-8.41 | $-8.59–$-8.23 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds FGEN.
No tracked institution reports a position in FGEN as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-06-17 | 1-for-25reverse |
No one on the platform has traded FGEN yet.
| $54M |
| — |
| MRSNMersana Therapeutics, Inc. | $29.08 | +0.00% | $145M | — |
| OKUROnKure Therapeutics, Inc. | $4.50 | +0.00% | $62M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at NaN× sales vs its 130.6× historical median P/S.
Fair value ≈ $-2392.97 · price $9.71 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.